Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma

[1]  S. Trestman,et al.  Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma , 2018, Bone Marrow Transplantation.

[2]  G. Visani,et al.  Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning , 2016, Leukemia & lymphoma.

[3]  G. Salles,et al.  Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT , 2016, Bone Marrow Transplantation.

[4]  G. Visani,et al.  Advancement in high dose therapy and autologous stem cell rescue in lymphoma. , 2015, World journal of stem cells.

[5]  Robert Chen,et al.  Brentuximab vedotin for the treatment of Hodgkin’s lymphoma , 2015, Expert review of hematology.

[6]  N. Schmitz,et al.  Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study , 2015, British journal of haematology.

[7]  S. Kvaløy,et al.  Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway , 2015, Haematologica.

[8]  A. Lane,et al.  Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  P. Veys,et al.  BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation , 2013, British journal of haematology.

[10]  J. Armitage,et al.  Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. , 2013, Clinical lymphoma, myeloma & leukemia.

[11]  I. Grotto,et al.  Autologous transplant in multiple myeloma with an augmented conditioning protocol , 2013, Leukemia & lymphoma.

[12]  S. Parmar,et al.  Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  A. LaCasce,et al.  Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant , 2012, Leukemia & lymphoma.

[14]  G. Serio,et al.  High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma , 2012, Clinical and Experimental Medicine.

[15]  Sang-We Kim,et al.  BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. , 2011, Leukemia research.

[16]  C. Moskowitz,et al.  Controversies in the treatment of lymphoma with autologous transplantation. , 2009, The oncologist.

[17]  K. Goodman,et al.  Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Slavin,et al.  The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation , 2007, Bone Marrow Transplantation.

[19]  H. Lazarus,et al.  Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? , 2007, Bone Marrow Transplantation.

[20]  N. Puig,et al.  Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation , 2006, Leukemia & lymphoma.

[21]  W. Hiddemann,et al.  Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Ball,et al.  High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma , 2004, Bone Marrow Transplantation.

[23]  J. Gribben,et al.  Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.